BioLineRx to Report Third Quarter 2026 Results on November 23, 2026
Management to Hold Conference Call at 8:30 a.m. EST
TEL AVIV, Israel, Nov. 18, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2026 on Monday, November 23, 2026, before the U.S. markets open.
The Company will host a conference call at 8:30 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer.
To access the conference call, please dial +1-888-407-2553 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until November 25, 2026; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.
About BioLineRx
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial has been initiated in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.
The Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide in solid tumors, including metastatic pancreatic cancer (PDAC), and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.
Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on LinkedIn.
CONTACTS:
United States
Chuck Padala
LifeSci Advisors, LLC
IR@biolinerx.com
Israel
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolinerx-to-report-third-quarter-2026-results-on-november-23-2026-302943733.html
This press release may not be republished, redistributed, resold or sublicensed without the prior written approval of PR Newswire.
AlphAI analysis
Written by AlphAI from the release above, not by the issuer or PR Newswire. Informational, not investment advice.
The 30-second read
Why it matters
The primary market impact is event-driven. The scheduled pre-market release and morning call can concentrate trading activity and increase implied volatility into Nov. 23.
Market read
Traders can use the disclosed date and call time to plan earnings-week risk management for BLRX.
What to watch
Options positioning, liquidity, and any pre-announcement leaks or analyst model changes are not covered here, but they can dominate near-term price action around the scheduled print.
Background
BioLineRx is a clinical-stage biopharmaceutical company with lead asset GLIX1 and an approved product APHEXDA (motixafortide), and it is providing logistics for its Q3 2026 results release.
Ticker impact
BioLineRx will release unaudited Q3 2026 results on Nov. 23, 2026 before the U.S. open and hold a call at 8:30 a.m. EST.
Likely volatility and positioning ahead of the Nov. 23 pre-market results, with direction dependent on the reported quarter and guidance commentary.
The article discloses only the release date/time and call logistics, not the quarter’s numbers, so the immediate tradable element is event timing rather than fundamentals.
Market effects
Limited sector read-through, as it is a single-company scheduled results announcement without new clinical or regulatory outcomes.
Minimal, despite the company’s Israel listing, since the key catalyst is the U.S. pre-market earnings release.
Low, as the news is company-specific and does not introduce cross-market policy or supply shocks.
Counterpoint
Because the release is scheduled and the article contains no new financial or clinical datapoints, traders may treat it as routine and focus on other catalysts (trial updates, partnership news).
Key entities
- companyBioLineRx Ltd.
NASDAQ-listed biopharmaceutical company announcing Q3 2026 results timing and conference call details.
- personPhilip Serlin
CEO scheduled to remark on the conference call at 8:30 a.m. EST.